 Hypoxia-inducible factor 1, HIF-1, has been recognized as an important cancer drug target. Recent studies show correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. This article was authored by Georgina N. Masoud and Weili.